TABLE 5.
ELISA IFN-γ responses to LSA-1 peptides and risk of adverse clinical outcome, adjusted for age, hemoglobin S level, and prior infectiona
| Clinical outcomeb | LSA-1 T3 peptide
|
LSA-1 9-mer peptides
|
Any LSA-1 peptide
|
|||
|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
| Clinical malaria | 0.15 (0.03-0.77) | 0.02 | 0.56 (0.11-2.86) | NS | 0.23 (0.08-1.25) | NS |
| Clinical malaria with high-density parasitemia | 0.10 (0.01-0.68) | 0.02 | 1.37 (0.28-6.71) | NS | 0.30 (0.06-1.40) | NS |
| Anemia (at time of sample collection) | 0.54 (0.08-3.71) | NS | 1.62 (0.22-11.72) | NS | 0.51 (0.07-3.84) | NS |
| Anemia (at 36-week follow-up) | 0.49 (0.07-3.57) | NS | 0.13 (0.01-1.36) | NS | 0.08 (0.01-0.77) | 0.03 |
a
All ORs and P values were calculated by logistic regression analysis. NS, not significant.
b
High-density parasitemia is defined as >4,000 P. falciparum parasites/μl of blood. Anemia is defined as <11 g of hemoglobin/dl of blood.